Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho guanine nucleotide exchange factor 33 (ARHGEF33)
- Target
- ARHGEF33
- Molecular classification
- Guanine nucleotide exchange factor (GEF), Enzyme, Rho GTPase activator
01
Overview
Rho guanine nucleotide exchange factor 33 (ARHGEF33) is a member of the RhoGEF protein family, serving as a GEF that activates Rho GTPases such as RhoA by catalyzing the exchange of GDP for GTP. This activation modulates cytoskeletal dynamics, cell shape, migration, and contraction. ARHGEF33 shows prominent expression in Müller glial cells in the developing retina and appears to regulate cell morphology and migration through small GTPase signaling. Although no drugs directly target ARHGEF33, the broader family is implicated in pathways relevant to cell signaling and disease, and ARHGEF33 is considered a candidate for studying cellular processes involving cytoskeletal remodeling.
- Other names
- ARHGEF33Rho guanine nucleotide exchange factor (GEF) 33ARG33_HUMANDH and coiled-coil domain-containing protein ENSP00000381780
02
Mechanism of action
For potential drugs (or analogs): inhibition or modulation of GEF activity, affecting RhoA-mediated cytoskeletal dynamics
03
Biological functions
Signal transductionCytoskeletal organizationCell morphology and migrationCell contractionRegulation of cell behaviorInhibition of neurite extension
04
Disease associations
Potentially involved in developmental processes (e.g., foveal formation in retina)Association with disease and phenotype according to functional and GWAS datasetsNo specific major disease associations clearly confirmed; general involvement suggested in cancer (by analogy to RhoGEFs)
05
Safety considerations
Not well characterized; as with other RhoGEF inhibitors, possible concerns could include impact on cell migration, cytoskeletal integrity, and tissue development (speculative)
06
Biomarkers
Expression enrichment in Müller glial cells during foveal development (retinal tissue)Potential mRNA/protein detection for tissue specificity
Beyond the preview
Go deeper on Rho guanine nucleotide exchange factor 33 (ARHGEF33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rho guanine nucleotide exchange factor 33 (ARHGEF33).